WORLD PEPTIDEFOUNDATION
← Master Registry

Non-peptide comparator · published research references

Orforglipron

Governed scientific comparator

4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

This reference comparator is not classified as a peptide.

Approved source records

  1. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

    DOI: 10.1056/nejmoa2302392

    Source identity and connection checked by Codex (AI).

  2. Emerging pharmacotherapies for obesity: A systematic review.

    DOI: 10.1124/pharmrev.123.001045PMID: 39952695

    Source identity and connection checked by Codex (AI).

  3. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

    DOI: 10.1056/nejmoa2511774

    Source identity and connection checked by Codex (AI).

  4. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

    DOI: 10.1056/nejmoa2505669

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Wharton S
  • Aronne LJ
  • Stefanski A
  • Alfaris NF
  • Ciudin A
  • Yokote K
  • Halpern B
  • Shukla AP
  • Zhou C
  • Macpherson L
  • Allen SE
  • Ahmad NN
  • Klise SR
  • ATTAIN-1 Trial Investigators
  • Rosenstock J
  • Hsia S
  • Nevarez Ruiz L
  • Eyde S
  • Cox D
  • Wu WS
  • Liu R
  • Li J
  • Fernández Landó L
  • Denning M
  • Ludwig L
  • Chen Y
  • ACHIEVE-1 Trial Investigators
  • Blevins T
  • Connery L
  • Raha S
  • Ma X
  • Mather KJ
  • Haupt A
  • Robins D
  • Pratt E
  • Kazda C
  • Konig M
  • GZGI Investigators
  • Kokkorakis M
  • Chakhtoura M
  • Rhayem C
  • Al Rifai J
  • Ghezzawi M
  • Valenzuela-Vallejo L
  • Mantzoros CS